当前位置: 首页 > 详情页

Engineering Energy-Responsive Magnetic Nanomaterials to Improve the Efficacy of Dendritic Cell-Based Immunotherapy

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Northwest Univ, Minist Educ, Prov Key Lab Biotechnol Shaanxi Prov, Xian 710069, Shaanxi, Peoples R China [2]Natl Med Prod Adm, Ctr Drug Evaluat, Beijing 100022, Peoples R China [3]Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, Beijing 100053, Peoples R China [4]Xi An Jiao Tong Univ, Affiliated Hosp 1, Med X Inst, Inst Regenerat & Reconstruct Med, Xian 710049, Shaanxi, Peoples R China [5]Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaanxi Prov Ctr Regenerat Med & Surg Engn, Natl Local Joint Engn Res Ctr Precis Surg & Regen, Xian 710061, Shaanxi, Peoples R China
出处:

关键词: antigen presentation dendritic cell immunogenic death magnetic nanoparticles tumor immunotherapy

摘要:
Effective diagnosis and treatment of cancer is still a great challenge to modern medicine. The advent of immunotherapy is revolutionizing the field of cancer research while drug toxicity and low responsive rates have become the most serious concerns in current treatment regimes. Dendritic cells (DCs) are the strongest antigen-presenting immune cells and play an important role in the initiation and regulation of the immune response. They can engulf a variety of foreign substances, including cell lysates and nucleic acids, and present antigens to activate the immune system. Some nanomaterials in vitro activation systems for DCs provide new ideas for immune-related therapies for tumors. Among these, magnetic nanoparticles (MNPs) have gradually become a major focus of basic scientific research and clinical treatment due to their advantages of good biocompatibility, low toxic side effects, and high ability to respond to external stimulus. The emergence of MNPs provides a novel, safe, and effective way to enhance the anti-tumor immune response. In this review, the application of MNPs as platform materials combined with DC immunotherapy is discussed, with the intention of providing a reference for future disease immunotherapy.

基金:

基金编号: 82072063 31901003 2019JC-27 2022KJXX-09 2020JQ610

语种:
WOS:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2021]版:
Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Northwest Univ, Minist Educ, Prov Key Lab Biotechnol Shaanxi Prov, Xian 710069, Shaanxi, Peoples R China
通讯作者:
通讯机构: [1]Northwest Univ, Minist Educ, Prov Key Lab Biotechnol Shaanxi Prov, Xian 710069, Shaanxi, Peoples R China [4]Xi An Jiao Tong Univ, Affiliated Hosp 1, Med X Inst, Inst Regenerat & Reconstruct Med, Xian 710049, Shaanxi, Peoples R China [5]Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaanxi Prov Ctr Regenerat Med & Surg Engn, Natl Local Joint Engn Res Ctr Precis Surg & Regen, Xian 710061, Shaanxi, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院